Axitinib versus sorafenib in advanced renal cell carcinoma: Subanalyses by prior therapy from a randomised phase III trial Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Imidazoles
  • Indazoles
  • Kidney Neoplasms
  • Niacinamide
  • Phenylurea Compounds
  • Protein Kinase Inhibitors

abstract

  • AXIS data suggest that longer duration of the first-line therapy generally yields better outcome with the second-line therapy and that lack of response to first-line therapy does not preclude positive clinical outcomes with a second-line vascular endothelial growth factor-targeted agent in patients with advanced RCC.

publication date

  • June 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4056058

Digital Object Identifier (DOI)

  • 10.1038/bjc.2014.244

PubMed ID

  • 24823696

Additional Document Info

start page

  • 2821

end page

  • 8

volume

  • 110

number

  • 12